MARC details
| 000 -LEADER |
| fixed length control field |
06387nam a22003017i 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
| control field |
20201006113307.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
| fixed length control field |
200217s2019 ii a|||| |||| 001 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
| International Standard Book Number |
9789352704965 |
| 040 ## - CATALOGING SOURCE |
| Original cataloging agency |
EG-NcFUE |
| Description conventions |
rda |
| 082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER |
| Classification number |
615.7 |
| Item number |
B.H.E |
| Edition number |
23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
| Personal name |
Baweja, Himanshu |
| Relator term |
author |
| 245 10 - TITLE STATEMENT |
| Title |
Essentials of pharmacovigilance / |
| Statement of responsibility, etc |
Himanshu Baweja ; Forwards Sangeeta Sharma, Yatin Mehta. |
| 250 ## - EDITION STATEMENT |
| Edition statement |
First edition |
| 264 #1 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
| Place of publication, distribution, etc |
New Delhi, |
| Name of publisher, distributor, etc |
JAYPEE BROTHERS MEDICAL P, |
| Date of publication, distribution, etc |
2019. |
| 300 ## - PHYSICAL DESCRIPTION |
| Extent |
xxv, 225 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
24 cm |
| 336 ## - CONTENT TYPE |
| Source |
rdacontent |
| Content type term |
text |
| 337 ## - MEDIA TYPE |
| Source |
rdamedia |
| Media type term |
unmediated |
| 338 ## - CARRIER TYPE |
| Source |
rdacarrier |
| Carrier type term |
volume |
| 500 ## - GENERAL NOTE |
| General note |
Includes Index. |
| 505 0# - FORMATTED CONTENTS NOTE |
| Formatted contents note |
1. Pharmacovigilance: A Complete Study about<br/>the Knowledge of Adverse Drug Reaction 1<br/> Categorization of Adverse Drug Reactions (ADRS): Based on Intensity 2<br/> Why Pharmacovigilance in India? 4<br/> Why Do We Need Pharmacovigilance? 4<br/> Who Program for International Drug Monitoring 5<br/> Specific Aims of Pharmacovigilance 6<br/> Global Perspective of Pharmacovigilance 6<br/> Scope of Pharmacovigilance Program of India 7<br/> Major Aims of Pharmacovigilance 7<br/>2. History of Pharmacovigilance 11<br/> Origin of Pharmacovigilance (PV) 11<br/> History 12<br/>3. Aim and Importance of Pharmacovigilance 19<br/> Aim of Pharmacovigilance 19<br/> Objective of Pharmacovigilance 19<br/> Definition of Adverse Drug Reaction (ADR) and Its Types 20<br/> Importance of Pharmacovigilance 21<br/> International Response to Drug Safety Issues 23<br/> Major Challenges 24<br/>4. Role of Healthcare Professionals in Pharmacovigilance 27<br/> HCPS and ADRS Reporting 29<br/>5. Importance of Pharmacovigilance in<br/>Special Groups such as Infants, Elderly and Pregnant Women 35<br/> Drug Monitoring in Special Population 36<br/> Drugs Prescribed in Pregnancy 36<br/>6. Legal Aspects of Pharmacovigilance 41<br/> Global Regulations in Pharmacovigilance 42<br/> Summary of Product Characteristics (SPC) 42<br/> Pharmacovigilance: Toward the Next Millennium 42<br/>7. Pharmacovigilance Programme of India 45<br/> The Indian Pharmacopoeia Commission (IPC) 46<br/> Pharmacovigilance Programme of India 46<br/> WHO–UMC (Uppsala Monitoring Centre) and India 48<br/>8. Practical Aspects of Pharmacovigilance Practices at Corporate Hospital 51<br/> Introduction of Clinical Pharmacology Department 51<br/> Why Clinical Pharmacists are Required in Hospital? 52<br/> Objective of Clinical Pharmacology Department 53<br/> Responsible Staff Involved in Clinical Pharmacology Department 53<br/> Role of Clinical Pharmacology Department 53<br/> Drug Information Center 54<br/> Pharmacovigilance Center 54<br/> Standard Operating Procedures (SOP) of<br/>Clinical Pharmacology Department in Hospital 54<br/> Monitoring on Electronic Information System (E-Prescription) 57<br/> Report and Documentation 57<br/>9. Medication Errors, Its Practical<br/>Analysis and Resolution 59<br/> Types of Medication Errors Involved 60<br/> Root Cause Analysis of Medication Error 60<br/> Corrective and Preventive Action 61<br/> Six Rights of Medication Safety 61<br/> Categorization of Medication Errors 61<br/> Definition and Levels of Adverse Drug Reaction (ADR) 61<br/> Practical Analysis of Medication Errors 62<br/> Practical Resolution of Medication Errors 63<br/>10. Recording and Reporting of Adverse Drug Reactions 65<br/> Methods of ADR Reporting 65<br/> Spontaneous Reporting 67<br/> Good Reporting Practices 68<br/> Suspected ADR Reporting Form 68<br/> ICSR and Its Detailed Components 69<br/> ADR Reporting Form for Healthcare Professionals 72<br/> Who Can Report? 73<br/> Why to Report? 73<br/> What to Report? 73<br/> How and Whom to Report? 73<br/> Characteristics of a Good Case Report 73<br/> Limitations of Spontaneous Reporting in India 74<br/> Recent Initiatives to Enhance the Reporting in PVPI 74<br/> Establishment of an AMC 75<br/> Data Flow and Establishment of AMC 75<br/> Assessment of Individual Case Safety Reports 75<br/> Utilization of the Data 76<br/> Reporting Requirements in Special Population 77<br/> Reporting in the Event of a Public Health Emergency 77<br/> Reports of Overdose, Abuse, Off-Label Use, Misuse or OTC 78<br/>11. Periodic Safety Update Report 79<br/> Common Forms in Pharmacovigilance 80<br/> Definitions of Various Terminologies Used in Common<br/>Forms in Pharmacovigilance Across World 81<br/> Severity Versus Seriousness 81<br/> Causality Assessment 83<br/> Prescribing Information 83<br/> Global Regulations in Pharmacovigilance 85<br/> Databases and Commercial Software<br/>Tools Used in Pharmacovigilance 85<br/>12. Causality Assessment of Drugs and Medical Devices: Logic and Method 87<br/> Materiovigilance 88<br/> Why Causality Assessment of Medical Devices 88<br/> Causality Assessment Scales 89<br/> Causality Term: Assessment Criteria 90<br/> Indian Regulation of Drug/All Medical Devices Adverse Event Reporting 91<br/> General Design of Causality Assessment2,3 92<br/> Four Basic Criteria 92<br/> Various Conditions in Causality Assessment 92<br/>13. Cure To Prescription: E-Prescription 97<br/> Purpose of Prescription 98<br/> Electronic Prescription (E-Prescription) 98<br/>14. Drug–Drug Interactions in Tertiary Care Hospital 105<br/> Epidemiology 106<br/> Severity of Drug–Drug Interactions 106<br/> Risk Factors of Drug–Drug Interactions 106<br/> Mechanism of Drug–Drug Interactions 107<br/> Effects: Hospital Stay and Cost 107<br/> Prevention 115<br/> Corrective Measures 116<br/>15. Therapeutic Drug Monitoring 117<br/> Drug Therapy Monitoring 118<br/> Clinical Review of Medication Administration Chart 120<br/> Ward Round Participation 120<br/> Role of Pharmacist in the Management of ADRS 121<br/> Patient Counseling 121<br/> Clinical Usefulness of TDM 122<br/>16. Postmarket Surveillance Program Concepts, Goals and Practices 123<br/> Postmarket Surveillance for Medical<br/>Devices-Associated Adverse Events 125<br/> Components of a Postmarket Surveillance Program 126<br/> A Model Postmarket Surveillance Program Structure 139<br/>17. Hemovigilance 143<br/> Objective of Reporting Adverse Reactions and<br/>Adverse Reactions in Transfusion 144<br/> Roles and Responsibilities of HVPI Units 144<br/>18. Case Studies (With Answers) 151<br/>Index 171 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
| Topical term or geographic name as entry element |
Pharmacoepidemiology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
| Topical term or geographic name as entry element |
Drugs |
| General subdivision |
Side effects. |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM |
| Topical term or geographic name as entry element |
Pharmaceutical Preparations |
| General subdivision |
adverse effects. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
| Personal name |
Sharma, Sangeeta |
| Relator term |
foreword |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
| Personal name |
Mehta, Yatin |
| Relator term |
foreword |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Books |